 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...2425262728293031323334...100101» |
- | letrozole / Generic mfg.
Journal: Molecular Cloning and Expression Responses of Jarid2b to High-Temperature Treatment in Nile Tilapia (Oreochromis niloticus). (Pubmed Central) - Oct 28, 2022
Further studies revealed that Jarid2b responded rapidly at the 8th hour after high-temperature treatment. Considering that JARID2 can recruit PRC2 and establish H3K27me3, we speculated that it might be an upstream gene participating in the regulation of Nile tilapia GSD + TE through regulating the H3K27 methylation level at the locus of many sex differentiation-related genes.
- Kisqali (ribociclib) / Novartis
Cell-cycle inhibition and immune microenvironment in HR+/HER2- breast cancer during and after preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial (Stars at Night Ballrooms 1&2) - Oct 28, 2022 - Abstract #SABCS2022SABCS_2000;
P2
Both treatments generally increased T- and B-cell immune infiltration; however, an inverse relationship between immune infiltration and anti-proliferative response at surgery exists according to treatment, where immune infiltration is increased in residual tumors with non-CCAA when treated with L+R, but the opposite is observed with CHT. The prognostic value of immune and anti-proliferative effects of L+R in residual tumors is currently being evaluated in the prospective RIBOLARIS phase II clinical trial (NCT05296746).
- Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
A Phase 3 study evaluating ovarian suppression following three-month leuprolide acetate in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA) (Hall 1) - Oct 28, 2022 - Abstract #SABCS2022SABCS_1924;
P3
Secondary endpoints include suppression of LH, E2 (< 20 pg/mL for tamoxifen cohort and < 2.72 pg/mL for AI cohort) and absence of menses at weeks 6, 12, 24, 36, and 48. NCT04906395
- Piqray (alpelisib) / Novartis
Baseline and end-of-treatment biomarkers in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from BYLieve Study Cohorts A and B (Hall 1) - Oct 28, 2022 - Abstract #SABCS2022SABCS_1888;
As the disease progressed, increases in loss-of-function mutations in PTEN at EOT in both Cohorts A and B suggested loss of PTEN in PI3K pathway may drive resistance to ALP. Early intervention with ALP, when the tumor is particularly driven by PIK3CA oncogenic mutations and before it develops more genomic complexity, may potentially provide better clinical outcomes.
- | letrozole / Generic mfg.
Preclinical, Journal: Kelulut Honey Improves Folliculogenesis, Steroidogenic, and Aromatase Enzyme Profiles and Ovarian Histomorphology in Letrozole-Induced Polycystic Ovary Syndrome Rats. (Pubmed Central) - Oct 28, 2022
Besides, the combination of KH with clomiphene was the most effective treatment in improving the ovarian histomorphology of PCOS rats. The effectiveness of KH in restoring altered folliculogenesis, steroidogenic, and aromatase enzyme profiles in PCOS warrants a future clinical trial to validate its therapeutic effect clinically.
- | letrozole / Generic mfg.
Journal: Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression. (Pubmed Central) - Oct 28, 2022
The third-generation aromatase inhibitor letrozole ameliorated liver fibrosis by suppressing the Yap-Ctgf pathway by partially modifying the Hsd17b13 and Cyp26a1 expressions, which reduced the retinoic acid level in the hepatocytes. The gene expression analysis using chimeric mice with humanized liver revealed that the mechanisms are letrozole specific and, therefore, may be repurposed for the treatment of liver fibrosis.
- || letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Evaluation of IM Letrozole ISM (clinicaltrials.gov) - Oct 28, 2022
P1, N=120, Active, not recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
The gene expression analysis using chimeric mice with humanized liver revealed that the mechanisms are letrozole specific and, therefore, may be repurposed for the treatment of liver fibrosis. Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2022 --> Mar 2023
- | letrozole / Generic mfg.
Journal: Extending letrozole treatment duration is effective in inducing ovulation in women with polycystic ovary syndrome and letrozole resistance. (Pubmed Central) - Oct 27, 2022
Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2022 --> Mar 2023 Extending LE treatment duration is a feasible method for inducing ovulation in women with PCOS and LE resistance.
- || Kisqali (ribociclib) / Novartis
Clinical data, Journal: Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. (Pubmed Central) - Oct 26, 2022
Extending LE treatment duration is a feasible method for inducing ovulation in women with PCOS and LE resistance. The present study supports the hypothesis that the concomitant use of PPIs does not compromise the efficacy of ribociclib in a real-life setting.
- ||| Kisqali (ribociclib) / Novartis
Trial completion, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Oct 26, 2022
P1, N=88, Completed, Sponsor: Novartis Pharmaceuticals
The present study supports the hypothesis that the concomitant use of PPIs does not compromise the efficacy of ribociclib in a real-life setting. Active, not recruiting --> Completed
- ||||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Clinical: COMPLEEMENT-1 of 1st line ribociclib and letrozole in HR+/HER2- MBC included 51 brain metastases pts. Time to progression similar in CNS group vs All pts. Intracranial endpoints not reported. (Cottu, The Breast 2022) #bcsm https://t.co/kzlJpspulI (Twitter) - Oct 25, 2022
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 25, 2022
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Dec 2022
- ||| Kisqali (ribociclib) / Novartis
Trial completion date: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Oct 25, 2022
P3, N=668, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Dec 2022 Trial completion date: Aug 2022 --> Dec 2022
- |||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases: BioItaLEE: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (clinicaltrials.gov) - Oct 24, 2022
P3, N=287, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Aug 2022 --> Dec 2022 Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jun 2024
- Ibrance (palbociclib) / Pfizer
A Single-Institution Cohort Study on Her2-Low Expression in Hormone-Receptor Positive Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase Inhibition by Palbociclib () - Oct 24, 2022 - Abstract #AMP2022AMP_623;
Her2- low disease was present in more than one-third of patients treated with palbociclib for metastatic breast cancer, and was found in various tumor tissue sites. Clinical benefit of palbociclib was high in our cohort, and lower in the small number of patients who also presented with BRCA mutations.
- letrozole / Generic mfg.
Laparoscopic oocyte retrieval for fertility preservation in a patient with squamous cell carcinoma of the vagina () - Oct 23, 2022 - Abstract #ESGE2022ESGE_788;
In order to limit high estrogens levels, letrozole has been used during the controlled ovarian stimulation (COS)...Laparoscopy oocyte retrieval, performed under regional anaesthesia, can be performed in ambulatory setting and could be considered an effective strategy to preserve fertility in patients and to prevent the risk of tumour spillage. https://player.vimeo.com/video/708292542?autoplay=1
- Ibrance (palbociclib) / Pfizer
A CASE OF PSEUDOCIRRHOSIS IN METASTATIC BREAST CANCER AFTER TREATMENT WITH PALBOCICLIB () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2198;
This case of pseudocirrhosis, with advanced GI and peritoneal metastases but no overt liver lesions, supports previous literature. The primary site of toxic injury is suspected to be sinusoidal endothelial cells with resultant circulatory compromise of centrilobular hepatocytes, fibrosis, and obstruction of liver blood flow.
- | Biomarker, Preclinical, Journal: Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers. (Pubmed Central) - Oct 22, 2022
Besides such endocrine therapy (ET) drugs, ERα-positive BCs can be treated with epidermal growth factor receptor (EGF-R) inhibitors (i.e., gefitinib, erlotinib, and lapatinib) according to HER2 expression...Here, we evaluated if other CGs could represent additional treatment options for ERα-positive BCs and if the Na/K ATPase could be considered a biomarker for ERα-positive BC treatment. The results indicate that the ATP1B3 Na/K ATPase isoform can educate the choice for the personalized treatment of ERα-positive BC with CGs and that CGs could be more efficacious if they are administered in association with gefitinib.
- | letrozole / Generic mfg.
Preclinical, Journal, Epigenetic controller: Protective Role of Acetate Against Depressive-Like Behaviour Associated with Letrozole-Induced PCOS Rat Model: Involvement of HDAC2 and DNA Methylation. (Pubmed Central) - Oct 22, 2022
The study demonstrates that PCOS-associated depression is characterised by neuroinflammation and elevated ACH levels, accompanied by increased expression of HDAC2/DNA methyltransferase in PFC and hippocampus. Besides, the study suggests that acetate protects against PCOS-associated depression through suppression of prefrontal and hippocampal DNA methylation and prefrontal but not hippocampal HDAC2 expression.
- ||| letrozole / Generic mfg., Verzenio (abemaciclib) / Eli Lilly
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer https://t.co/eawo3qNrFI (Twitter) - Oct 21, 2022
- letrozole / Generic mfg.
Sex hormones impact the response to immunotherapy in obese male mice. (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_361;
Obese males were treated with the aromatase inhibitor letrozole in order to decrease the estrogen/androgen ratio...Conclusions These results demonstrate that the estrogen/androgen ratio can determine the response to ICI in obese mice and support the hypothesis that sex hormones may contribute to ICI sensitivity in obese male patients with melanoma. This concept opens the path to investigate whether serum sex hormones levels could be used as biomarkers for response to ICI and whether targeting the hormonal balance may be a relevant therapeutic strategy to improve the response to ICI.
- | letrozole / Generic mfg.
Journal: Considerations when treating male pubertal delay pharmacologically. (Pubmed Central) - Oct 21, 2022
Aromatase inhibitors have arisen as an interesting alternative for boy with CDGP and short stature. Gonadotrophin therapy seems more physiological in patients with central hypogonadism, but its relative efficacy and most adequate timing still need to be established.
- || Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer (clinicaltrials.gov) - Oct 21, 2022
P2, N=75, Completed, Sponsor: University of Alabama at Birmingham
Gonadotrophin therapy seems more physiological in patients with central hypogonadism, but its relative efficacy and most adequate timing still need to be established. Trial completion date: Nov 2020 --> Mar 2022 | Trial primary completion date: Nov 2020 --> Mar 2022
- | letrozole / Generic mfg.
Journal: Facebook as a source of access to medicines. (Pubmed Central) - Oct 20, 2022
These were opioids (n = 7; 1.71%), benzodiazepines (n = 2; 0.48%), clomifene (n = 1; 0.24%), and letrozole (n = 1; 0.24%)...Medicines offered on Facebook were mainly accessible for free. The scope and the number of medications offered on Facebook should make this issue a hazardous phenomenon.
- | letrozole / Generic mfg.
Journal: Impact of Oral Ovulatory Induction Medications Among Female Military Members and Military Beneficiaries. (Pubmed Central) - Oct 20, 2022
The majority of side effects for oral ovulation induction medications were described as slight or mild. Therefore, this study provides evidence-based data of severity side effects that could be used to guide the waiver process and improve readiness for female aviators in the military.
- |||||| Inluriyo (imlunestrant) / Eli Lilly
Enrollment open: EMBER-4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (clinicaltrials.gov) - Oct 20, 2022
P3, N=6000, Recruiting, Sponsor: Eli Lilly and Company
Therefore, this study provides evidence-based data of severity side effects that could be used to guide the waiver process and improve readiness for female aviators in the military. Not yet recruiting --> Recruiting
- |||| letrozole / Generic mfg.
Clinical: MBC patient here... Had oophorectomy in 2017 while stable on Palbo and Letrozole (still nice and stable on said drugs). Why no gynae followup with this procedure...? Should I have had? I've had to battle to be seen to tackle problems that are not just "dryness"... (Twitter) - Oct 19, 2022
- letrozole / Generic mfg., tamoxifen / Generic mfg., capecitabine / Generic mfg.
PREVALENCE OF DRUG INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN CANCER PATIENTS () - Oct 19, 2022 - Abstract #AIOM2022AIOM_101;
Preliminary data from this study demon- strate the necessity of careful treatment evaluation to pre- vent poor clinical outcomes due to drug interactions and to avoid the prescription of potentially inappropriate drugs in elderly cancer patients, suffering from concomitant dis- eases. A drug interaction checker tool could improve clini- cal decision-making and patient safety.
- Kisqali (ribociclib) / Novartis
CIRCULATING TUMOR DNA (CTDNA) AND SERUM THYMIDINE KINASE 1 ACTIVITY (TKA) MATCHED DYNAMICS IN PATIENTS (PTS) WITH HORMONE RECEPTOR–POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2¬–NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) TREATED IN FIRST-LINE (1L) WITH RIBOCICLIB (RIB) AND LETROZOLE (LET) IN THE BIOITALEE TRIAL (Titian Room 3) - Oct 19, 2022 - Abstract #AIOM2022AIOM_53;
P3
Pts with ctDNA+/TKa+ are strongly enriched for non- responders. TKa and ctDNA capture different features of tumor biological activity and their combination warrants further evaluation in relation to other treatments, settings, and diseases.
- THE HOBOE MULTICENTER RANDOMIZED PHASE 3 TRIAL IN PREMENOPAUSAL PATIENTS (PTS) WITH HORMONERECEPTOR POSITIVE EARLY BREAST CANCER (EBC) COMPARING TRIPTORELIN PLUS EITHER TAMOXIFEN (T) OR LETROZOLE (L) OR ZOLEDRONIC ACID + LETROZOLE (ZL): 8YR EFFICACY ANALYSIS (Auditorium) - Oct 19, 2022 - Abstract #AIOM2022AIOM_3;
P3
clinicaltrials.gov: NCT00412022. Promoted by NCI Naples.
- | Ibrance (palbociclib) / Pfizer
Journal: Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. (Pubmed Central) - Oct 19, 2022
P3
Findings from PALOMA-4 support the efficacy and safety of first-line palbociclib plus letrozole in postmenopausal Asian women with ER+/HER2- ABC. No new safety concerns of palbociclib plus letrozole were identified.
- | Ibrance (palbociclib) / Pfizer
Journal: Oncology Drug Effectiveness from Electronic Health Record Data Calibrated Against RCT Evidence: The PARSIFAL Trial Emulation. (Pubmed Central) - Oct 18, 2022
Despite common challenges encountered in EHR-based studies, it is possible to achieve similar conclusions to emulated randomized trials with the application of analytic approaches that address missing data, confounding, and selection bias. This is a promising finding in light of other emulations and ongoing efforts to improve data from clinical practice and causal analytics.
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal: Induction of Endometrial HOXA 10 Gene Expression by Vitamin D and its Possible Influence on Reproductive Outcome of PCOS Patients Undergoing Ovulation Induction Procedure. (Pubmed Central) - Oct 18, 2022
On regression analysis adjusted for age and BMI, vitamin D was an independent predictor of successful pregnancy after OI (P = 0.09). Circulating vitamin D levels influence the endometrial HOXA10 gene expression, and this may be reflected on the reproductive outcome of infertile PCOS patients undergoing OI.
- | Piqray (alpelisib) / Novartis
Trial completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 18, 2022
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Circulating vitamin D levels influence the endometrial HOXA10 gene expression, and this may be reflected on the reproductive outcome of infertile PCOS patients undergoing OI. Trial completion date: Aug 2022 --> Oct 2023
- | New P1/2 trial: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Oct 17, 2022
P1/2, N=716, Not yet recruiting, Sponsor: Fudan University
- ||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Great Collaborative Job ! Data from Spanish Population of the CompLEEment-1 trial with Letrozole plus Ribociclib avalaible. 👇🏻https://t.co/fU2P7Tty9B (Twitter) - Oct 16, 2022
- | Ibrance (palbociclib) / Pfizer
Journal: Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. (Pubmed Central) - Oct 15, 2022
P2
The PARSIFAL data confirmed the favorable safety profile of both palbociclib regimens. VTE and ILD/pneumonitis were occasionally reported, and their early detection allowed patients to continue treatment effectively without detriment to efficacy.
- | letrozole / Generic mfg.
Preclinical, Journal: In vitro cytotoxicity and anti-cancer drug release behavior of methionine-coated magnetite nanoparticles as carriers. (Pubmed Central) - Oct 14, 2022
The appearance of a new peak for C≡N confirms the formation of Letrozole-loaded carrier in the FTIR...Also, the preparation had been evaluated for determining its cytotoxicity using MCF-7, MDA-MB-231, and MCF10A cells as an in vitro model, and the result vitro experiments showed that CoFeO@Methionine could significantly reduce cancer in cells model. These results demonstrate that core-shell nanoparticle was prepared is biocompatible and have potential use as drug delivery.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov) - Oct 14, 2022
P2, N=40, Not yet recruiting, Sponsor: National Cancer Centre, Singapore
These results demonstrate that core-shell nanoparticle was prepared is biocompatible and have potential use as drug delivery. Trial completion date: Mar 2026 --> Dec 2026 | Initiation date: Apr 2022 --> Jan 2023 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) - Oct 14, 2022
P2, N=38, Active, not recruiting, Sponsor: Emory University
Trial completion date: Mar 2026 --> Dec 2026 | Initiation date: Apr 2022 --> Jan 2023 | Trial primary completion date: Dec 2024 --> Dec 2025 Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- | Trial completion date, Trial primary completion date, Surgery: PLATO: PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate (clinicaltrials.gov) - Oct 13, 2022
P2, N=122, Recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023 Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2021 --> Oct 2023
- | Ibrance (palbociclib) / Pfizer
Retrospective data, Journal: Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. (Pubmed Central) - Oct 13, 2022
Following progression on a CDK 4/6i, mPFS was short, with similar PFS times comparing chemotherapy and ET, with slightly longer PFS for targeted strategies (PI3K/mTOR). These results highlight a major need to better understand the mechanisms of CDK4/6i resistance and identify new therapeutic strategies for these patients.
- || Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
Enrollment open, Trial completion date: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) - Oct 13, 2022
P2, N=48, Recruiting, Sponsor: Ruth O'Regan
These results highlight a major need to better understand the mechanisms of CDK4/6i resistance and identify new therapeutic strategies for these patients. Not yet recruiting --> Recruiting | Trial completion date: Aug 2024 --> Feb 2024
- || letrozole / Generic mfg.
Retrospective data, Review, Journal: Use of letrozole to augment height outcome in pubertal boys: a retrospective chart review. (Pubmed Central) - Oct 13, 2022
A small positive trend in PAH with letrozole therapy is augmented by simultaneous use of rhGH. Future randomized controlled trials are needed to better understand which group of patients will benefit from treatment.
- | letrozole / Generic mfg.
Preclinical, Journal: Delayed Implantation Induced by Letrozole in Mice. (Pubmed Central) - Oct 12, 2022
Progesterone supplementation could rescue decidualization failure in the mice. Collectively, we established a new model of delayed implantation by letrozole, which can be easily applied to study the effect and mechanisms of delay of embryo implantation on the progression of late pregnancy events.
- | letrozole / Generic mfg.
Journal: Evaluation of Different Doses of the Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy and Its Effect on Villous Trophoblastic Tissue. (Pubmed Central) - Oct 12, 2022
The utilization of letrozole at a dose of 10 mg day for medical treatment of ectopic pregnancy results in a high-successful rate without any severe side effects. Letrozole depriving the placenta of estrogen that had vascular supporting signals resulted in destroying the vascular network with marked apoptosis.
- || PF-07248144 / Pfizer
Trial completion date, Trial primary completion date, Metastases: C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 12, 2022
P1, N=108, Recruiting, Sponsor: Pfizer
Letrozole depriving the placenta of estrogen that had vascular supporting signals resulted in destroying the vascular network with marked apoptosis. Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Nov 2023 --> May 2024
- | Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date: Palbociclib and FES PET (clinicaltrials.gov) - Oct 12, 2022
P2, N=30, Completed, Sponsor: University Medical Center Groningen
Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Nov 2023 --> May 2024 Active, not recruiting --> Completed | Trial completion date: May 2022 --> Sep 2022 | Trial primary completion date: May 2022 --> Sep 2022
- | chlorogenic acid / Jiuzhang Biotech
Preclinical, Journal: Therapeutic Investigation of Standardized Aqueous Methanolic Extract of Bitter Melon (Momordica charantia L.) for Its Potential against Polycystic Ovarian Syndrome in Experimental Animals' Model: In Vitro and In Vivo Studies. (Pubmed Central) - Oct 11, 2022
HPLC analysis of standardized aqueous methanolic extract of bitter melon revealed the presence of various phytochemicals such as quercetin, gallic acid, benzoic acid, chlorogenic acid, syringic acid, p-coumaric acid, ferulic acid, and cinnamic acid...Letrozole (1 mg/kg p.o.) was used for four weeks to induce PCOS in twenty rats...Animals were further divided into four groups, with one group as PCOS group, and the remaining three are treated with standardized extract of bitter melon (500 mg/kg p.o.), bitter melon plus metformin (500 mg/kg p.o.), and metformin alone for the period of next four weeks...Lipid profile and antioxidant enzymes status were also significantly (p < 0.001) improved. In conclusion, the study validates the bitter melon potential as an insulin sensitizer and ovulation enhancer and authenticates its potential in PCOS management.
- Ibrance (palbociclib) / Pfizer
Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) outcomes in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- ABC): Exploratory analysis of the PARSIFAL Trial (Stars at Night Ballroom 1&2) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1861;
Observational, retrospective studies on concomitant PPI with PAL or ribociclib showed a shorter progression-free survival (PFS) among PPI users than nonusers...Methods Pts with endocrine- sensitive HR+/HER2- ABC and no prior therapy in advanced setting were randomly assigned to receive PAL (hard capsule formulation) plus either fulvestrant or letrozole...Despite the post-hoc nature of the study, these findings suggest pharmacokinetic interactions between PPI and PAL capsules. Further confirmatory studies including the tablet formulation of PAL, which is expected to assure its optimal absorption, are needed.